A top-20 global pharmaceutical company with a diverse portfolio spanning cardiovascular, oncology, immunology, and rare diseases. The company invests billions annually in R&D, commercialization, and global expansion strategies. To maintain leadership, it must ensure that its strategic priorities align with evolving patient, physician, and payer needs before committing significant resources.
Pharmaceutical strategy is shaped by multiple, often conflicting forces: patient needs, physician prescribing behavior, payer reimbursement criteria, and regulatory scrutiny. The company needed clarity on which therapeutic areas offered the greatest opportunity for future investment, how patients and physicians perceived unmet needs within those areas, what value propositions and outcomes would resonate most with payers, and whether strategic assumptions aligned across markets, segments, and stakeholders.
Traditional strategic validation through advisory boards, payer councils, and KOL interviews was time-consuming, often requiring months to recruit and execute, expensive due to costly honoraria, logistics, and third-party facilitation, and limited in scope, as feedback from small groups could miss critical perspectives.
Zibble enabled the pharma company to stress-test its strategic priorities at scale before committing resources. By creating AI personas of patients living with chronic and rare diseases, physicians across specialties including oncology, cardiology, and primary care, and payers balancing cost-containment and value-based care, the company was able to conduct instant qualitative interviews to uncover perspectives on unmet needs, treatment preferences, and value communication.
The company tested strategic investment areas across oncology, immunology, and neurology simultaneously across multiple markets. It identified misalignments, for example physicians emphasizing treatment adherence while payers focused on cost offsets. And it validated whether proposed strategic initiatives such as new therapy launches, patient support programs, and digital health tools aligned with stakeholder priorities.
Zibble transformed how the company validated strategy across several dimensions. It confirmed that oncology expansion aligned with both patient demand and payer willingness to reimburse. It prevented costly missteps by deprioritizing investments in therapeutic areas with limited stakeholder alignment. It highlighted gaps between patient, physician, and payer perspectives, ensuring strategies addressed all three. It surfaced cultural differences, with patients in Asia prioritizing affordability while European payers emphasized long-term outcomes. And it delivered insights in weeks instead of months, allowing the executive team to adjust its five-year strategy with speed, while reducing reliance on repeated advisory boards and in-market pilots.
Within weeks, the pharma company validated its strategic roadmap, ensuring that its top investment areas were grounded in authentic, multi-stakeholder insights. The leadership team moved forward with confidence, knowing their strategy reflected not only market potential, but also the voices of patients, physicians, and payers.
